NCT03448042 : A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Breast,Female reproductive organs,Stomach and upper gastrointestinal tract,Urinary systemBladder,Breast,Cervix,Gallbladder,Gastro-oesophageal junction ,Oesophagus,Stomach

Trial Overview Read MoreRead more

This phase I trial is evaluating a new intravenous drug (BTRC4017A) in patients with locally advanced or metastatic HER2-expressing cancers.
 

This trial is treating patients with HER2-expressing cancers.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

Commercial Sponsor

Genentech

Summary

This trial involves a dose escalation and expansion phase. In the dose escalation phase, patients will be assigned sequentially to escalating doses of BTRC4017A, up to the maximum tolerated dose (MTD). In the dose expansion phase, patients will receive receive BTRC4017A based on the MTD or maximum allowed dose (MAD) identified during dose escalation.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next